# Study Investigating the Safety, Tolerability, and PK, PD, of CB-0406

> **NCT04467684** · PHASE1 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 90 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** CB-0406 100 mg
- **DRUG:** CB-0406 200 mg
- **DRUG:** CB-0406 400 mg
- **DRUG:** CB-0406 800 mg
- **DRUG:** CB-0406 1,000 mg
- **DRUG:** Matched placebo

## Key facts

- **NCT ID:** NCT04467684
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-07
- **Primary completion:** 2021-05-30
- **Final completion:** 2021-06-06
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2021-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04467684

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04467684, "Study Investigating the Safety, Tolerability, and PK, PD, of CB-0406". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04467684. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*